ArticleQuantitative imaging in medicine and surgery2026
Volume ratio factor: a novel CT-derived biomarker for pre-planning ipsilateral lung dose risk stratification in breast cancer radiotherapy.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ipsilateral lung dose in breast cancer radiotherapy is typically evaluated only after treatment planning, limiting early risk stratification and planning optimization. This study aimed to develop and validate a novel computed tomography (CT)-derived volumetric biomarker, the volume ratio factor (VRF), for pre-planning assessment of ipsilateral lung dose risk in breast cancer radiotherapy. Methods: In this retrospective single-center study, 58 breast cancer patients receiving volumetric modulated arc therapy (VMAT) with regional nodal irradiation (RNI) were analyzed. VRF was defined as the ratio of lung internal volume (LIV) to ipsilateral lung volume (ILV) using simulation CT. Correlation analyses were performed between VRF and lung dose metrics, and predictive performance was compared with conventional anatomical parameters using receiver operating characteristic (ROC) analysis and machine learning regression models. Results: VRF demonstrated the strongest correlation with mean lung dose (MLD) among all evaluated anatomical parameters (r=0.582, P<0.01), with significant correlation also observed for V20 (r=0.485, P<0.01) and V10 (r=0.438, P<0.01). ROC analysis showed that VRF achieved the highest discriminative performance for identifying patients with MLD >13 Gy [area under the curve (AUC) =0.71]. Regression analyses further demonstrated stable predictive performance with low estimation error using repeated cross-validation [mean absolute error (MAE): 0.51±0.10 Gy; mean absolute percentage error (MAPE): 4.22%±0.90%]. Compared with seven conventional anatomical parameters, VRF reduced MAE and MAPE by 19.5% and 20.9%, respectively, across all regression frameworks and lung dose-volume endpoints. In the subgroup without internal mammary node (IMN) irradiation, the correlation between VRF and MLD further increased to r=0.637. Conclusions: VRF is a simple and interpretable CT-derived biomarker that captures three‑dimensional target‑lung spatial interaction. It enables pre‑planning risk stratification of ipsilateral lung dose and may support geometry‑informed, individualized radiotherapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.